Zenas BioPharma Reports Positive Phase 3 Obexelimab Results in IgG4-RD
WALTHAM, Mass., June 2, 2026 Zenas BioPharma, Inc. announced positive results from its registrational Phase 3 INDIGO trial evaluating...
ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
WALTHAM, Mass., June 2, 2026 Zenas BioPharma, Inc. announced positive results from its registrational Phase 3 INDIGO trial evaluating...
